Opening book details…
Can I read Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update on EtoBox?
Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update by Husam M. Salah; Subhi J. Al'Aref; Muhammad Shahzeb Khan; Malek Al-Hawwas; Srikanth Vallurupalli; Jawahar L. Mehta; J Paul Mounsey; Stephen J. Greene; Darren K. McGuire; Renato D. Lopes; Marat Fudim is a Medicine article available to read on EtoBox.
What is Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update about?
In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.
Who reads Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Husam M. Salah; Subhi J. Al'Aref; Muhammad Shahzeb Khan; Malek Al-Hawwas; Srikanth Vallurupalli; Jawahar L. Mehta; J Paul Mounsey; Stephen J. Greene; Darren K. McGuire; Renato D. Lopes; Marat Fudim
- Publisher
- Elsevier BV
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)